Trial · NCT03481959
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
NCT03481959, Phase 3, Terminated, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity. Trials, record NCT03481959. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03481959
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
- NCT number
- NCT03481959
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 3 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Methylphenidate, Matching Placebo
- First posted
- 2018-03-29
- Last updated
- 2022-04-25
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of days of use of cannabis | 12 weeks | Number of days of use of cannabis in the past 21 days measured in 12 weeks by the TimeLine Follow Back (TLFB 21) |
| Secondary | Number of days of use of cannabis | 4,8,12 weeks and 12 months | The average amount of daily consumption of cannabis within the past 21 days will be assessed from the TLFB 21-4, 8, 12 weeks and 12 months |
| Secondary | Average daily consumption of cannabis in the last 21 days | 4,8,12 weeks and 12 months | will be evaluated from the TLFB 21. The TLFB 21 makes it possible to quantify the number of daily cannabis |
| Secondary | ADHD Rating scale IV score | 4,8,12 weeks and 12 months | The scale evaluates the frequency of behavior, the level of behavioral discomfort and the developmental level. |
| Secondary | advanced CAST score | one day, 12 weeks and one year | The CAST is a 6-item scale, each of which describes use behaviors or problems encountered in the context of cannabis use |
| Secondary | the score of the Hooked on nicotine checklist (HONC) | one day, 4,8,12 weeks and 12 months | HONC is a self-administered questionnaire that assesses nicotine addiction. |
| Secondary | the score of French version of the Tobacco Craving Questionnaire (FTCQ-12) | one day, 4,8,12 weeks and 12 months | Evaluation of tobacco craving from the four primary factors of tobacco craving: emotionality, craving in anticipation of withdrawal relief or negative mood; waiting, compulsion and anticipation |
| Secondary | Psychiatric comorbidities | one day, 12 weeks and 12 months | |
| Secondary | Consumption of other drugs | one day, 12 weeks and 12 months | |
| Secondary | Score of Overall Clinical Improvement Scale (CGI-S) | one day, 4,8,12 weeks and 12 months | Measurement of symptom severity, response to treatment and efficacy of treatment in treatment studies of patients with mental disorders. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35201607 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03481959
GET https://conductscience.org/api/trials/v1/NCT03481959/registered